Liquidia shares plunged nearly 50% after a US court ruled against the company in a patent dispute with United Therapeutics, raising concerns over Yutrepia’s commercial prospects.
Why is Liquidia stock plunging? Yutrepia patent case explained
Published ·
Keep reading
Related stories
